Trial reportJournal of cosmetic dermatology2025
A Multi-Center Clinical Trial to Evaluate the Efficacy of the Next Generation TriHex Technology Antiaging Regimen.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist-Related Facial Aging.The Journal of clinical and aesthetic dermatology · 2026Article
- TriHex Technology and Reversal of Solar Elastosis: Dispelling Some Myths.Journal of cosmetic dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAlastin Restorative Skin Complex Serum with TriHex Technology (Alastin Skincare Inc., Carlsbad, CA) has undergone reformulation to add Octapeptide-45 and magnolol for improving facial skin hydration, elasticity, plumping, and overall skin quality. Detailed science on TriHex Technology 2.0 and magnolol has been recently published. This open-label study was conducted to validate the science and demonstrate product efficacy and tolerability in individuals with moderate to severe facial skin aging.
methodsA multi-center clinical study was conducted from February to August 2024. A total of 44 eligible participants (43 female, 1 male), ages 35-69 years, and Fitzpatrick skin Types I-VI were enrolled in and completed the study following 12 weeks of Alastin Restorative Skin Complex Serum 2.0 with TriHex Technology (RSC 2.0) use twice daily, along with an Alastin Skincare Inc. supportive regimen (cleanser, moisturizer, sunscreen used as needed). A 1-week run-in phase using the supportive regimen only was conducted, and eligibility was reassessed at baseline. Follow-up visits were performed at Weeks 4, 8, and 12, where facial skin quality parameters were evaluated clinically and subject assessments and satisfaction questionnaires, biopsy collection, photography, and hydration and elasticity measurements were completed. Participants also maintained a study diary over the 12-week treatment period.
resultsSignificant improvements for all clinically evaluated facial skin parameters were achieved at Week 12. Histology revealed increased stimulation of new adipocytes, epidermal keratinocyte HA (CD44), and new dermal collagen and elastin fibers post treatment.
conclusionAlastin Restorative Skin Complex Serum 2.0 with TriHex Technology has been demonstrated to be safe and effective for improving overall facial skin quality, achieving notable improvements in volume, plumping, hydration, and extracellular matrix (ECM) collagen and elastin stimulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.